Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.
CITATION STYLE
Ohri, N. (2017, September 21). Radiotherapy dosing for locally advanced non-small cell lung carcinoma: “MTD” or “ALARA”? Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2017.00205
Mendeley helps you to discover research relevant for your work.